It is likely that HL12 and HL32, which was derived from an antibody identified through in vivo screening based on autoimmunity and immunotherapeutic efficacy, may have other features that needs to be explored for optimal CTLA-4 antibodies. The gene discussed is CTLA4; the disease is Autoimmunity.